

Chemical Proteomics-based Approach for Drug Target Discovery in Living Systems

胡良海

吉林大学生命科学学院

E-mail: lianghaiu@jlu.edu.cn


Outline

- 1. Introduction drug target discovery**
- 2. Identification of drug target in live cells by chemical proteomic approach**
- 3. Tyrosine kinase/phosphatase substrate**

Outline

- 1. Introduction drug target discovery**
- 2. Identification of drug target in live cells by chemical proteomic approach**
- 3. Tyrosine kinase/phosphatase substrate**

Drug Discovery Pipeline



High-throughput Screening

The collage features several key elements:

- Top Left:** A chemical structure of a nucleotide derivative with a red arrow pointing to a specific atom.
- Top Center:** A 96-well microplate with colored spots, a chemical reaction scheme with fragments A, B, and C, and a multi-channel pipette.
- Top Right:** A ribbon diagram of a protein structure, colored red and blue.
- Middle Left:** A 3D ribbon model of a protein structure with various residues labeled (L5, B4, 137, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200).
- Middle Center:** A large robotic workstation in a laboratory setting.
- Middle Right:** A chemical structure of a ligand with a central atom 'A' bonded to R¹, R², and R³, and a ³H label.
- Bottom Left:** A multi-channel pipette and a plate reader.
- Bottom Center:** A large piece of laboratory equipment, possibly a synthesizer or reactor, with a computer monitor.
- Bottom Right:** A plate reader.

High Throughput Screening & Combinatorial Chemistry


ADP **Mg** **L5** **(R)-man-9f**

© Roman LOPEZ 2007

The Nature of Drug Target




**Who came first ?
Drug or target**




Bead-based Chemical Proteomics


(1) Prepare affinity column




(2) Apply protein source to affinity column



(3) Fish for binding proteins



(5) Identify proteins by mass spectrometry



(4) Separate binding proteins

MW Binding
marker proteins



Why living systems ?




Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease

***Chem Biol.* 2005; 12(12): 1259-1268**

***Nat Biotechnol.* 2005; 23(10): 1303-1307**

***Proc Natl Acad Sci USA.* 2007; 104(11): 4389-4394**




Activity-Based Protein Profiling (ABPP)



Tag

Linker

Reaction group



Prof. Benjamin F. Cravatt, The Scripps Research Institute

Prof. Matthew Bogoy, Stanford University

Outline

1. Introduction to drug target discovery
- 2. Identification of drug target in live cells by chemical proteomic approach**
3. Tyrosine kinase/phosphatase substrate

Intracellular protein target *in vivo*




Identification of Drug Targets In Vitro and in Living Cells by Soluble-Nanopolymer-Based Proteomics

Lianghai Hu, W. Andy Tao, et al.


Angew. Chem. Int. Ed. 2011, 50(18):4133-4136

(Selected as “hot paper” by the editor)





Dendrimer-based Nanomedicine

1. Excellent solubility
2. High structural/chemical homogeneity
3. Compact spherical shape
4. High branching
5. Controlled surface functionalities
6. Ability to permeate cells
7. Low cytotoxicity




In vivo characterization of protein targets



Hu L, Tao WA, et al. *Angew. Chem. Int. Ed.*, , 50(18):4133-4136
(DOI:10.1002/anie.201006459, Selected as "Hot Paper" by the Editor)

Identification of the therapeutic protein targets




Choose Dendrimer Generation




G3 Dendrimer




G4 Dendrimer



G5 Dendrimer



G6 Dendrimer




G7 Dendrimer



Insulin




Cytochrome C



Hemoglobin




Transthyretin



Histone


MTX-DHFR System: A Case Study







MTX: an antifolate drug in treatment of cancer by inhibiting the metabolism of folic acid



DHFR: required for the *de novo* synthesis of purines, thymidylic acid and certain amino acids

Deficiency of DHFR is linked to *megaloblastic anemia* disease`






Capture of the endogenous DHFR *in vitro* from cell lysate using dendrimer-MTX



Identification of DHFR by MS/MS




In-gel digestion for
MS analysis

32.44% coverage of the
whole sequence of DHFR


VDMVWIVGGSSVYK
LLPEYPGVLSDVQEEK
NGDLPWPPLR
LTEQPELANK
EAMNHPGHLK
TWFSIPEK
SLDDALK
MTTSSVEGK

SILAC quantification for the differentiation of protein target and non-specific binding



Combine the heavy with light together and then on-bead digest for MS analysis

Classification of all the proteins identified by mass spectrometry



Known targets:

1. Dihydrofolate reductase
2. Deoxycytidine kinase



Potential targets:

1. Aspartate aminotransferase
2. Trifunctional purine biosynthetic protein adenosine-3


High abundant non-specific binding proteins:

1. Tubulin beta-2C chain
2. 40S ribosomal protein S3
3. Elongation factor
4. Heat shock protein

Flow cytometry for the deliver efficiency of the dendrimer reagent into living cells





Human B cell-DG 75




HeLa cell


Fluorescence microscopy imaging analysis



In vivo characterization of protein targets



Two known target DHFR and Deoxycytidine kinase can be successfully identified from living cells




**MS/MS spectrum of a peptide—LLPEYPGVLSDVQEEK
from DHFR which is identified *in vivo***

ITAM: Immunoreceptor Tyrosine-based Activation Motif


| | | | | | | | | | |
|--|-------|---|-------|-----|-----------|---|-------|-----|-------|
| CD3γ | DQL | Y | QP | L | KDREDDQ- | Y | SH | L | QGN |
| CD3δ | DQV | Y | QP | L | RDRDDAQ- | Y | SH | L | GGN |
| CD3ϵ | NPD | Y | EP | I | RKGQRDL- | Y | SG | L | NQR |
| TCRζ_1 | NQL | Y | NE | L | NLGRREE- | Y | DV | L | DKR |
| TCRζ_2 | EGL | Y | NE | L | QKDKMAEA | Y | SE | I | GMK |
| TCRζ_3 | DGL | Y | QG | L | STATKDT- | Y | DA | L | HMQ |
| Igα (hMB-1) | ENL | Y | EG | L | NLDDCSM- | Y | ED | I | SRG |
| Igβ (hB29) | DHT | Y | EG | L | DI DQTAT- | Y | ED | I | VTL |
| FcϵRI-β | DRV | Y | EE | L | NI YSAT-- | Y | SE | L | EDP |
| FcϵRI-γ | DGV | Y | TG | L | STRNQET- | Y | ET | L | KHE |
| Consensus | - - - | Y | - - - | L/I | - - - - - | Y | - - - | L/I | - - - |

Tandem phosphorylated tyrosine residues of ITAM will bind to the Src Homology 2 (SH2) domain of other receptor proteins associated with activation, survival, and differentiation

Catalog of SH2-containing proteins




Syk (spleen tyrosine kinase) as a model study



Kuil J, et al. *Adv. Exp. Med. Bio.*, 2009, 611, 81-82

Recruitment of Syk to the diphosphorylated γ -ITAM of high affinity IgE receptor (Fc ϵ RI) results in activation of its kinase domain


Biphosphorylated ITAMs induce protein tyrosine phosphorylation in B cells




J Immunol. 1995 Nov 15;155(10):4596-603.

Affinity enrichment ability of ITAM peptide to Syk protein

DG 75 cells w and w/o stimulation of pervanadate




WB: Anti-Syk



WB: 4G10


SILAC quantification for the differentiation of non-specific bindings and protein targets




| | Ratio(L/H) |
|--|-------------------|
| Crk-like protein (coding a protein exhibiting the SH2 domain) | 100 |
| Tyrosine-protein kinase CSK | 100 |
| 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-1 | 100 |
| Tyrosine-protein kinase SYK | 100 |
| Phosphatidylinositol 3-kinase regulatory subunit alpha | 100 |
| Tyrosine-protein kinase ZAP-70 | 100 |
| Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 1 | 100 |

Traditional competitive assay


SPR detection





binding curve



Dr. Jacob Piehler, Biocenter Frankfurt




Quantitative proteomics for competitive binding assay by mass spectrometry





Physiological condition & high throughput

Protein digest as the internal standard



Determination of the binding affinity of ITAM peptide to multiple proteins





Relative binding affinity can be got by fitting the target protein concentration with different amount of free ITAM competitor

Outline

1. Introduction to drug target discovery
2. Identification of drug target in live cells by chemical proteomic approach
3. Tyrosine kinase/phosphatase substrate

Tyrosine kinase/phosphatase substrate



In vitro Kinase Substrate Screening






Fig. 1 Strategy for detections of on-chip phosphorylation. (A) Peptide immobilization method. (B) Outline of the detection of on-chip phosphorylation.





B cell receptor signaling




| | | | | |
|-------------------|--|---|---|--|
| Substrates | ARHGDI1A, BLNK, CAPN1, Ck2, DCTN2, DOK1, EZR, FGFR1OP, HCLS1, LAT2, MAP1B, NUCKS1, PAG1, PDAP1, PIK3R1, PRPF31, PTPN1, SET, STK4 | HCA59, CALM1, CLNS1A, COPB2, DDX41, EEF2, HBS1L, LRBA, NFYA, PAWR, PJA2, PQBP1, SEC23IP, SFRS8, TACC3, TMEM49, TUBA1B, TUBA1C, ZRANB2 | ARAP1, CDC5L, CLIC1, IK, PDCD4, POU2AF1, SF3A1, SF3B1, SLC4A1AP, TRIM28 | DPF2, EIF3J, ERCC6L, NSFL1C, PDCL3, RAD21, TRIP4 |
| | Biological functions | Hematological System Development and Function, Inflammatory Response | Cell Death, Infection Mechanism, Cell Morphology | Infection Mechanism, Cellular Movement, Lipid Metabolism |

141 tyrosine-phosphorylated peptides from 63 proteins in 3 mg of whole human B cell DG75 cell extract




Confirmation of Syk kinase substrates




A) Centrosomal co-localization of GFP fused Syk with tubulin
B) The subcellular location of GFP-Syk fusion protein under oxidation stress.


JAK2/PTP substrate




Both pY1007 and pY1008 can be dephosphorylated




Single dephosphorylation site was found short time reaction





JAK2 peptide was dephosphorylated sequentially






Identify the JAK2 peptide dephosphorylation site by MS²






Does PTP recognize the phosphosite specifically ?





Compare the dephosphorylation efficiency of different phosphosites




Dephosphorylation efficiency
 $1008 > 1007 + 1008 > 1007$


Summary

- ❖ PTP can dephosphorylate both pY1007 and pY1008.
- ❖ PTP prefer to catalyze the 1008 site.
- ❖ pY1008 enhance the dephosphorylation of pY1007 by binding to the PTP domain.

Investigation of PTP substrates by proteomics



pY WB



Thanks for your attention !

